Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 iito 560x80px
Document › Details

Agilent Technologies Inc.. (6/18/19). "Press Release: New State-of-the-Art Facility Increases Agilent’s Capacity to Produce Nucleic Acid-Based Therapeutics". Santa Clara, CA.

Region Region Denver, CO
  Country United States (USA)
Product Product oligo synthesis
Person Person Goumillout, Naomi (Agilent 201710)
     


New facility in Frederick, Colorado, to produce high-quality molecules with the potential to treat cancer and other diseases


Agilent Technologies Inc. (NYSE: A) today announced the opening of a production facility in Colorado that more than doubles its capacity to develop and manufacture "oligos," which are short DNA and RNA molecules that customers use to produce nucleic acid-based therapeutics.

Agilent expects the demand for therapeutic oligo manufacturing to grow near 10% each year through 2025, to over $750 million by 2025. This facility will enable Agilent to meet this growing demand and to continue being a partner of choice to pharmaceutical and biotech companies. Shipments to customers from this new site are expected by year-end.

The new state-of-the-art facility is in Frederick, about 30 miles north of Denver. It produces oligonucleotide ("oligo") active pharmaceutical ingredients, which hold the potential to treat cancer, rare and infectious diseases, cardiovascular indications, and other disorders.

"Our customers are developing innovative therapies that can lead to truly life-changing outcomes for patients," said Brian Carothers, vice president of Agilent's Nucleic Acid Solutions Division. "As a leading oligo manufacturer for over 20 years, Agilent is uniquely qualified to support this critical and growing industry. Our Frederick facility ensures we will keep up with demand while continuing to deliver a premium customer service."

"We're committed to Frederick and the state of Colorado," added Carothers. "Agilent has already brought 100 high-paying jobs to Frederick. Depending on customer demand, the site can further expand its manufacturing capacity in the coming years."

The $185 million facility in Frederick covers 135,000 square feet. It also expands Agilent's presence in Colorado, where the company has had an oligo manufacturing site in nearby Boulder since 2006. Both sites are current Good Manufacturing Practices (cGMP) facilities, as designated by the U.S. Food and Drug Administration.

For more information visit the Agilent Frederick Media Room.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,550 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.


Contact

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

   
Record changed: 2019-08-15

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Agilent (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Open BEU2019 650x80px




» top